Effect of Real-world Tight Control Management of Inflammatory Bowel Disease

McMaster University logo

McMaster University

Status

Withdrawn

Conditions

Inflammatory Bowel Diseases

Treatments

Diagnostic Test: Fecal calprotectin
Other: Routine care

Study type

Interventional

Funder types

Other

Identifiers

NCT03633669
4

Details and patient eligibility

About

Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, is a condition that causes inflammation in the gastrointestinal tract. The disease goes through periods of remission and flare. Biomarkers such as fecal calprotectin have been proposed as a tool to monitor disease activity. Fecal calprotectin is a test that measures the amount of inflammation in the stool. Monitoring fecal calprotectin levels can assist gastroenterologists in making decisions regarding patients' IBD treatment such as whether to increase the dose of medications. A recent study showed that frequent measurement of fecal calprotectin every 3 months, also called the tight-control strategy, was associated with improved clinical outcomes in IBD patients. The purpose of this study is to assess whether the tight-control monitoring strategy, which includes fecal calprotectin monitoring every 3 months, improves clinical outcomes in IBD when performed in the real world compared to routine clinical practice.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of Crohn's disease or ulcerative colitis based on clinical, endoscopic, radiologic or histologic criteria.
  • Followed by a gastroenterologist at Hamilton Health Sciences, St. Joseph's Healthcare Hamilton, and London Health Sciences
  • Aged 18 or older
  • In clinical remission according to the clinical symptom assessment (Partial Mayo score < 2 or Harvey-Bradshaw Index < 4)
  • Currently treated with adalimumab

Exclusion criteria

  • Current abdominal abscess
  • Inability or unwillingness to provide informed consent
  • Any other condition, which in the opinion of the investigators would impede competence or compliance or possibly hinder completion of the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups, including a placebo group

Tight control
Active Comparator group
Description:
Group that will receive fecal calprotectin testing every 3 months
Treatment:
Diagnostic Test: Fecal calprotectin
Standard care
Placebo Comparator group
Description:
Routine clinical care
Treatment:
Other: Routine care

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems